Paul W. Browning, Ph.D.

パートナー

+1 202 408 4134 +1 202 408 4134
paul.browning@finnegan.com paul.browning@finnegan.com

901 New York Avenue, NW
Washington, DC 20001-4413

vCard

Show Paul's work in

主に化学、製薬分野の特許訴訟、控訴を中心業務とする。米国連邦地方裁判所のあらゆる法廷で審理事件を扱い、仲裁及び調停手続きも手掛ける。公判、マークマン・ヒアリング、及び控訴審では主任弁護士として訴訟チームを牽引する。

幅広い訴訟経験には、公判での証人尋問、終局的判断を求める申立書の作成及び弁護、控訴趣意書の作成、控訴審での弁護を含む。また、複数の当事者が関与する係争事件の訴訟アクティビティを日々管理する。さらに、権利化手続のコーディネート、米国及び海外で発生した訴訟への戦略構築、等様々な特許問題で助言する。

Patent Resources Group Inc.化学特許実務コースの講師。シカゴ大学で修士号及び博士号を取得する際、レーザーシステムの設計及び小分子の分光分析を実施した。

業務の一環として積極的にプロボノ活動に携わり、現在、弊所プロボノ委員会の委員長を務める。軍関係者の代理人として、戦闘中の負傷等、兵役中に被った負傷に対する損害賠償の増額を求める弁護を担う。また、合衆国退役軍人請求控訴裁判所、連邦巡回控訴裁判所で退役軍人の代理人も務める。

Et Cetera

大塚製薬株式会社のブロックバスターエビリファイ®をめぐる複数の訴訟で同社を代理。ディスカバリ手続から、公判前準備、公判での証人尋問に至るまで、日常ベースで同事件の訴訟業務を手掛けた。
2000年 – 2001年連邦巡回控訴裁判所のGlenn L. Archer, Jr.判事の法務書記を務めた。
シカゴ大学にて修士号および博士号を取得する過程においてレーザーシステムの設計と小分子の分光分析を研究した。

Select Publications

共著 “The Implications of Danisco for Patent Owners,” Massachusetts Lawyers Weekly, Nov. 6, 2014.
共著 “GSK v. Banner Pharmacaps, Inc.: A Refresher on Adequate Written Description Support for Structural Limitations in Chemical Claims,” AIPLA Chemical Practice Chronicles Newsletter, Fall 2014.
共著 “Subject Matter Jurisdiction in Patent Cases Not Dependent on ANDA Certification Requirement,” Westlaw Journal Intellectual Property, March 5, 2014.
共著 “Patenting Headache When Employee-Inventor Leaves,” Today’s General Counsel, Feb./March 2014.
共著 “A Closer Look at the Post-Ariad Written Description Requirement,” Intellectual Property Today, Nov. 2012.

実績

Represented Biogen in a Hatch-Waxman litigation involving 28 companies seeking FDA approval to market generic versions of Tecfidera^®.

1:17-cv-00829, D. Del., Judge Noreika
1:17-cv-00116, N.D.W. Va., Judge Keeley

Represented Vifor and American Regent in two Hatch-Waxman Act cases against Mylan and Sandoz regarding their attempts to obtain FDA approval for their respective ANDAs directed to generic copies of Injectafer®. After a six-day bench trial, the cases resulted in a favorable settlement for our clients with a generic entry date well past the expiration of the composition patents.

3:19-cv-13955, 3:19-cv-16305, D.N.J., Judges Wolfson, Arpert

Represented Ferring in inventorship litigation, relating to desmopressin pharmaceutical compositions, acting as co-lead counsel at trial.

1:12-cv-02650, S.D.N.Y., Judges Cott, Sweet

Represented Otsuka in 24 related Hatch-Waxman litigations concerning Otsuka’s Ability® tablet products and acted as lead counsel on appeal.

1:14-cv-01078, -04671, -02982, -07405, -05878, -06398 -08074 -03306, -06890, -05876, -08077, -03168, -07252, -07105 -05537, -03996, -06158, -04508, -04307, -06397, -07106, -01979, -03445; 1:15-cv-0161, -07584, -01585, -07803, -08830, -05109, -07802, -08955, -01716, -01967, -06353, -08305; 1:16-cv-05288, -05400, -05949, -07705 -02475, -02476, -08284, -05743, -00086, -08085, -00555, -00557, -07346, -06067, -00405, -00424, -05688, -09603; 1:17-cv-02754, -00392, D.N.J., Judges Simandle, Williams

Prosecuting patents for startup Hutchison Medipharma

Finnegan prepared and prosecuted patents for startup Hutchison Medipharma in the United States for the treatment of metastatic colorectal cancer. Those patents cover a small molecule, fruquintinib, which received approval in China.

Completed successful patent prosecution for Principia. By entrusting Finnegan to obtain strong patents for their Phase 1 candidate, Principia was able to secure an exclusive, worldwide license agreement with Sanofi to develop and commercialize PRN2246, with the potential for $765 million in milestone payments. Finnegan also successfully prosecuted patents directed to compound PRN1008, a BTK inhibitor that Principia is investigating for autoimmune and inflammatory diseases. Principia’s impressive pipeline of drug candidates, covered by a patent portfolio prosecuted by Finnegan, led to an IPO in which Principia raised over $100 million.